Alligator Bioscience AB

Posted: May 7, 2016 at 5:55 pm

Warning

Our new website is optimized for the most current web browsing technology. If you are using an older web browser, part of our website may not function properly as designed. Please consider upgrading your browser for an error free experience.

Drug Development Candidate ADC-1004 has been shown to reduce myocardial infarction in a porcine ischemia reperfusion injury model. As part of the d

Alternativa Aktiemarknaden har trots ptryckningar frn Alligator Bioscience beslutat att nnu inte upphra med noteringen p Alternativas han

Alligatorbuilds value by using its proprietary human scFv antibody library ALLIGATOR-GOLD and the FIND technology platform to develop innovative antibody-based immuno-oncology compounds for unmet medical needs within cancer. Alligator Bioscience is focusing on discovery and early development phases and is growing an attractive pipeline of drug development candidates in various stages of preclinical and clinical development. ALLIGATOR-GOLD is a fully human synthetic kappa scFv library with large diversity (10 billion unique clones). ALLIGATOR-GOLD has been validated by selection of functionally active antibodies with sub-nanomolar affinities against several targets. FIND (Fragment Induced Diversity) technology is a powerful in vitro based antibody and protein optimization technology that creates functional libraries from which optimal variants of potential drug development candidates can be selected. ALLIGATOR-GOLD and FIND are fully integrated to give Alligator Bioscience the competitive advantage to develop immuno-oncology compounds with higher probability of success.

About us

Board of Directors

Management

Scientific Advisors

Carrer

ADC-1013 is an antibody-based immunotherapy, inducing anti-tumor immune effects through the activation of CD40 on antigen-presenting cells. ADC-1013 is currently in clinical phase I: safety and tolerability is assessed in a clinical trial of late stage cancer patients at 5 clinical sites in Europe. ADC-1013 was out-licensed to Janssen Biotech in August 2015.

ADC-1015 is a bispecific immuno-oncology compound. The drug candidate is based on the concept that the properties of two complementary immune activatingentities, OX40 and CTLA-4,are united into one moleculeto induce superior immune activation. Manufacturing for clinical trials was initiated in January 2016. ADC-1015 is currently in pre-clinical development.

ADC-1016 is a bispecific tumor-localizing immunotherapy, composed of one tumor-targeting moiety and one immune activatingmoiety. Immune activation is dependent on binding to the tumor target which reduces the risk of systemic toxicity. ADC-1016 is in late research phase.

Excerpt from:
Alligator Bioscience AB


Comments are closed.

Archives